Visioneering Technologies Inc (ASX:VTI)
A$ 0.1 -0.01 (-9.09%) Market Cap: 5.61 Mil Enterprise Value: 2.47 Mil PE Ratio: 0 PB Ratio: 0.84 GF Score: 0/100

Visioneering Technologies Inc at NWR Virtual Small Cap Investor Conference, Series 2 Transcript

May 23, 2020 / NTS GMT
Laura Daquino
NWR Communications - Moderator

(audio in progress) virtual health conference on May 1, 2020. We've got Visioneering Technologies up next. And Visioneering Technologies is an innovative eyecare company committed to redefining vision. Headquartered in the US, Visioneering designs, manufactures, sells, and distributes contact lenses. Its flagship product is the NaturalVue multifocal contact lens. And VTI has expanded its portfolio of technologies to address a range of eyecare issues.

On the line from Atlanta, where's it quite late over there, we have Dr. Stephen Snowdy, who's the CEO. Dr. Snowdy is a scientist, serial entrepreneur, and medical venture capitalist with 17 years of experience in life science investing and executive management. He previously served as CEO at Abby Med, a start-up pharmaceutical company dedicated to the development of a novel class of cancer drugs. He was also Chairman, CEO of Calosyn Pharma, a Phase 2 osteoarthritis company, and was a partner for several years at a top-tier medical venture capital firm.

Stephen, I might throw to you. You can take it

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot